Key Dates

Related Announcements

• May 5, 2020 - Research Project Grant (Parent R01 Clinical Trial Required). See NOFO PA-20-183.
• May 5, 2020 - Research Project Grant (Parent R01 Clinical Trial Not Allowed). See NOFO PA-20-185.

Issued by

National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

Purpose

The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) is committed to maximizing the scientific impact of its investments in investigator-initiated biomedical research to advance the understanding of the causes, treatment, and prevention of arthritis and musculoskeletal and skin diseases. To address this goal, the Institute strives to support a broad portfolio of meritorious research grants within the NIAMS’ mission.

Effective with fiscal year 2025 applications, all new and renewal R01 applications in response to the NIH parent R01 Notices of Funding Opportunity (NOFOs) will be considered low program priority if the principal investigator (PI) has three or more active R01-equivalent grants (R01-equivalent grants are defined as activity codes DP1, DP2, DP5, R01, R37, R56, RF1, RL1, U01 and R35), either funded by NIAMS, or another NIH Institute, Office, or Center (ICO). The policy will apply to R01 applications from Multiple PIs (MPIs) if one of the MPIs has three or more active R01-equivalent grants.  Possible exceptions are:

• If the R01 is a competing renewal application for a NIAMS funded R01, or
• If one or more of the existing active grant(s) will expire in < 1 year resulting in two or fewer active R01equivalent awards, or
• If existing active R01-equivalent awards are all from other NIH ICOs

Inquiries

Please direct all inquiries to:

Please direct your inquiries to the appropriate NAIMS staff supporting the NIAMS scientific programs (Supported Scientific Programs | NIAMS (nih.gov))